- Previous Close
33.10 - Open
31.70 - Bid 32.50 x 33100
- Ask 32.90 x 32100
- Day's Range
31.70 - 32.50 - 52 Week Range
26.20 - 39.50 - Volume
139 - Avg. Volume
92 - Market Cap (intraday)
519.782M - Beta (5Y Monthly) 0.68
- PE Ratio (TTM)
13.16 - EPS (TTM)
2.47 - Earnings Date May 22, 2025 - May 26, 2025
- Forward Dividend & Yield 1.57 (4.73%)
- Ex-Dividend Date Jul 16, 2024
- 1y Target Est
--
Clínica Baviera, S.A., a medical company, operates a network of ophthalmology clinics in Spain and Europe. The company is involved in the diagnosis, treatment, and monitoring of various types of visual disorders. Its clinics offers myopia, hyperopia, astigmatism, farsightedness, presbyopia, cataract, retinal, plastic surgery, pediatric ophthalmology, glaucoma, strabismus, cornea, neuro-ophthalmology, tear ducts, oculoplasty, lasik, lasek, and intraocular lenses treatments. The company was formerly known as Clínica Oftalmológica Baviera, S.L. and changed its name to Clínica Baviera, S.A. in 2000. Clínica Baviera, S.A. was incorporated in 1992 and is headquartered in Madrid, Spain. Clínica Baviera, S.A. is a subsidiary of Aier Eye International (Europe), S.L.U.
www.clinicabaviera.com1,706
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: D9Z.F
View MorePerformance Overview: D9Z.F
Trailing total returns as of 4/9/2025, which may include dividends or other distributions. Benchmark is IBEX 35... (^IBEX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: D9Z.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: D9Z.F
View MoreValuation Measures
Market Cap
524.58M
Enterprise Value
493.20M
Trailing P/E
13.40
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.05
Price/Book (mrq)
5.46
Enterprise Value/Revenue
1.88
Enterprise Value/EBITDA
6.32
Financial Highlights
Profitability and Income Statement
Profit Margin
15.13%
Return on Assets (ttm)
17.81%
Return on Equity (ttm)
43.16%
Revenue (ttm)
265.72M
Net Income Avi to Common (ttm)
40.2M
Diluted EPS (ttm)
2.47
Balance Sheet and Cash Flow
Total Cash (mrq)
38.58M
Total Debt/Equity (mrq)
59.67%
Levered Free Cash Flow (ttm)
41.14M